{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:52:15Z","timestamp":1758120735288,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K07418","21K08161"],"award-info":[{"award-number":["19K07418","21K08161"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.yexcr.2022.113078","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T20:50:53Z","timestamp":1645217453000},"page":"113078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations"],"prefix":"10.1016","volume":"413","author":[{"given":"Miki","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9300-6185","authenticated-orcid":false,"given":"Sachie","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-1726","authenticated-orcid":false,"given":"Masashi","family":"Idogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-1359","authenticated-orcid":false,"given":"Yuji","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2022.113078_bib1","article-title":"MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.yexcr.2022.113078_bib2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113078_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102173","article-title":"Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies","volume":"95","author":"Wu","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.yexcr.2022.113078_bib4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2022.113078_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"GEOMETRY mono-1 investigators. Capmatinib in MET exon 14-mutated or MET -amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2022.113078_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2022.113078_bib7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bbrc.2010.03.120","article-title":"Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion","volume":"394","author":"Asaoka","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2022.113078_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-A necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.yexcr.2022.113078_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2014.10.133","article-title":"Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells","volume":"454","author":"Yamaguchi","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2022.113078_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2017.04.102","article-title":"Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma","volume":"487","author":"Yamaguchi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2022.113078_bib11","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexcr.2022.113078_bib12","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41388-018-0226-z","article-title":"Capillary morphogenesis gene 2 maintains gastric cancer stem-like cell phenotype by activating a Wnt\/\u03b2-catenin pathway","volume":"37","author":"Ji","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2022.113078_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/path.5062","article-title":"Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma","volume":"245","author":"Tan","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexcr.2022.113078_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2022.113078_bib15","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/s41598-021-84787-5","article-title":"Pancancer survival analysis of cancer hallmark genes","volume":"11","author":"Nagy","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2022.113078_bib16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00432-014-1650-2","article-title":"Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis","volume":"140","author":"Ye","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2022.113078_bib17","article-title":"How we treat patients with metastatic HER2-positive breast cancer","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.yexcr.2022.113078_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2022.01.002","article-title":"Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer","volume":"61","author":"Nakajima","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.yexcr.2022.113078_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-Generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482722000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482722000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:40:31Z","timestamp":1757997631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482722000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0014482722000714"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113078","relation":{},"ISSN":["0014-4827"],"issn-type":[{"type":"print","value":"0014-4827"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113078"}}